151585-95-4

Basic information

• Product Name: Benzaldehyde, 2-amino-6-methoxy- (9CI)
• Synonyms: Benzaldehyde, 2-amino-6-methoxy- (9CI);2-AMino-6-Methoxybenzaldehyde
• CAS NO: 151585-95-4
• Molecular Formula: C₈H₉NO₂
• Molecular Weight: 151.16256
• Product Categories: ALDEHYDE
• Mol File: 151585-95-4.mol

Chemical Properties

• Boiling Point: 312.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.186±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -0.07±0.10(Predicted)
• CAS DataBase Reference: Benzaldehyde, 2-amino-6-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 2-amino-6-methoxy- (9CI)(151585-95-4)
• EPA Substance Registry System: Benzaldehyde, 2-amino-6-methoxy- (9CI)(151585-95-4)

Safety Data

• Hazardous Substances Data: 151585-95-4(Hazardous Substances Data)

Upstream product

• 53600-33-2 6-methoxyanthranilic acid 
• 177531-95-2 2-amino-6-methoxyl-benzyl alcohol 
• 19689-88-4 2-methoxy-6-nitrobenzaldehyde 

Downstream Products

• 130194-92-2 9-hydroxy-(20RS)-camptothecin 

Relevant articles and documents

DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

DIHYDROQUINAZOLINONE ANALOGUES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Synthesis of quinolinomorphinan derivatives as highly selective δ opioid receptor ligands

We have reported previously the novel δ opioid agonist KNT-127 which showed high affinity and selectivity for the δ receptor. Moreover, the analgesic effect of subcutaneously administered KNT-127 was more potent than that of a prototypical δ agonist (-)-TAN-67 in the acetic acid writhing test. This study of the structure-activity relationship of KNT-127 derivatives focused on the introduction of substituents onto the 5′-, 6′-, 7′- or 8′-position of the quinoline ring and revealed that many derivatives with 5′- or 8′-substituents showed high affinities and selectivities for the δ receptor. Especially, SYK-153 with an 8′-OH group showed the highest affinity and the most balanced and highest selectivity for the δ receptor among the synthesized compounds.